Central Retinal Vein Occlusion in the Absence of Conventional Risk Factors Associated With Breast Carcinoma: A Case Report Authors: Hamna Danyal Barry, Erum Habib, Muhammad Umer Barry, Musfirah Danyal Barry, Ayesha Barkat, Husam Abu Dawood Published: 2026 ABSTRACT ABSTRACTCentral retinal vein occlusion in 41‐year‐old female patients without conventional risk factors should raise concern for systemic evaluation for underlying malignancy and treatment‐related hypercoagulability. Breast carcinoma and chemotherapy (e.g., capecitabine) may represent plausible contributing factors. Early recognition with intravitreal anti‐vascular endothelial growth factor therapy can significantly improve visual outcomes. Introduction Central retinal vein occlusion (CRVO) is the second most common retinal vascular disorder after diabetic retinopathy, typically affecting individuals over 50 years of age and strongly associated with systemic risk factors such as hypertension, diabetes mellitus, and hyperlipidemia [1]. The condition results from thrombotic occlusion of the central retinal vein, leading to venous congestion, retinal hemorrhages, macular edema, and vision loss. In younger patients, CRVO is relatively rare and often linked to hypercoagulable states, autoimmune disorders, or systemic malignancies [2]. Malignancy is a recognized prothrombotic condition in which tumor‐derived factors and chemotherapy agents contribute to abnormal clot formation [3]. Several cancers, including lung, renal, colorectal, and hematologic malignancies, have been associated with retinal vascular occlusion [4, 5]. More recently, Malvasi et al. described combined retinal vein and artery occlusion in a patient undergoing therapy for metastatic breast cancer, highlighting that retinal vascular events in breast carcinoma are increasingly recognized [6]. This case is educational because it highlights CRVO in a 41‐year‐old female with breast carcinoma, without conventional systemic risk factors. The novelty lies in the rare association between breast malignancy and retinal vascular occlusion, underscoring the importance of a systemic evaluation in atypical presentations of CRVO. Identifying malignancy as an underlying etiology is crucial, as timely ophthalmic and oncologic management can improve both visual and systemic outcomes. Case Presentation A 41‐year‐old female presented to the ophthalmology outpatient department with a complaint of sudden, painless diminution of vision in her left eye for the past 10 days. She had a known diagnosis of grade III invasive ductal carcinoma of the right breast and was undergoing treatment with oral capecitabine, an antimetabolite chemotherapeutic agent. Her past medical history was unremarkable for hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, or cerebrovascular events. She was a nonsmoker and had no family history of thromboembolic disorders. On general examination, her blood pressure was 128/88 mmHg, heart rate 99 beats per minute, and random blood glucose level 123 mg/dL. Systemic examination was otherwise unremarkable. Ophthalmic Examination Visual acuity (BCVA): 6/6 OD, 6/36 OS.Fundus (OS): Fundus examination revealed multiple flame‐shaped hemorrhages, optic disc swelling, and tortuous dilated retinal vessels in the left eye (Figure 1).OCT (OS): Macular edema, central thickness 478 μm; intraretinal fluid present, no subretinal fluid, retinal layers intact.Systemic workup: Normal BP, glucose, lipid profile, renal function, viral serology; Hb 10 g/dL. Thrombophilia and autoimmune screening were not performed, so alternative prothrombotic conditions cannot be fully excluded. Visual acuity (BCVA): 6/6 OD, 6/36 OS. Visual acuity (BCVA): 6/6 OD, 6/36 OS. Fundus (OS): Fundus examination revealed multiple flame‐shaped hemorrhages, optic disc swelling, and tortuous dilated retinal vessels in the left eye (Figure 1). Fundus (OS): Fundus examination revealed multiple flame‐shaped hemorrhages, optic disc swelling, and tortuous dilated retinal vessels in the left eye (Figure 1). OCT (OS): Macular edema, central thickness 478 μm; intraretinal fluid present, no subretinal fluid, retinal layers intact. OCT (OS): Macular edema, central thickness 478 μm; intraretinal fluid present, no subretinal fluid, retinal layers intact. Systemic workup: Normal BP, glucose, lipid profile, renal function, viral serology; Hb 10 g/dL. Thrombophilia and autoimmune screening were not performed, so alternative prothrombotic conditions cannot be fully excluded. Systemic workup: Normal BP, glucose, lipid profile, renal function, viral serology; Hb 10 g/dL. Thrombophilia and autoimmune screening were not performed, so alternative prothrombotic conditions cannot be fully excluded. Fundus examination of (A) right eye and (B) left eye. Investigations Optical coherence tomography (OCT) of the left eye demonstrated macular edema with a central macular thickness of 478 μm. Hematological investigations showed hemoglobin 10 g/dL (reference: 12–15 g/dL), white blood cell count 6.1 × 109/L (reference: 4.5–11.0 × 109/L), and platelet count 300,000/mm3 (reference: 150,000–400,000/mm3). Fasting lipid profile, renal function tests, and viral serology (HBsAg and anti‐HCV) were within normal limits. (Figure 2). Optical coherence tomography of both eyes. Oncological workup confirmed the diagnosis of breast carcinoma. Histopathology of the breast mass revealed grade III invasive ductal carcinoma with dermal lymphovascular invasion. CT chest demonstrated local extension of the carcinoma with metastatic lymphadenopathy involving the right supraclavicular, axillary, and subpectoral regions. Skeletal scintigraphy excluded bone metastasis. Diagnosis Based on clinical findings, OCT results, and exclusion of conventional systemic risk factors, a diagnosis of unilateral central retinal vein occlusion (CRVO) in the left eye was established. Breast carcinoma and chemotherapy were considered plausible contributing factors. Management and Follow‐Up The patient was initiated on intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy (Avastin). She received three monthly injections in the left eye. At follow‐up, her visual acuity improved to 6/9, with marked reduction in macular edema on OCT. Three months after the third injection, OCT showed central macular thickness reduced to 278 μm, with near‐complete resolution of intraretinal fluid and restoration of foveal contour. She continued systemic oncological management under the care of her oncology team. Post‐treatment OCT showed marked reduction in macular edema and restoration of foveal contour (Figure 3). Optical coherence tomography of the left eye demonstrating macular edema. Summary This case highlights a rare presentation of CRVO in a young female without conventional systemic risk factors, where breast carcinoma and its associated hypercoagulable state were considered possible contributing factors. Timely ophthalmic intervention with anti‐VEGF therapy resulted in favorable visual outcomes. Discussion Central retinal vein occlusion (CRVO) is a common retinal vascular disorder, second only to diabetic retinopathy, and is typically associated with older age and systemic comorbidities such as hypertension, diabetes, and hyperlipidemia [1]. Its occurrence in younger patients is rare and often prompts consideration of alternative etiologies, including thrombophilia, autoimmune disease, or systemic malignancy [2]. This case illustrates a plausible association between breast carcinoma and CRVO. Breast carcinoma and capecitabine therapy may have acted synergistically to increase thrombotic risk, but causality cannot be established in a single case report. Several malignancies have been linked to retinal vascular occlusion, including leukemia, hepatocellular carcinoma, renal cell carcinoma, lung cancer, and colorectal cancer [4]. In these reports, hypercoagulability was consistently identified as the underlying pathophysiological mechanism. Madanagopalan et al. described CRVO in a patient with breast carcinoma, highlighting malignancy‐induced thrombosis as the likely cause [7]. Similarly, Luo et al. reported CRVO in patients with metastatic solid tumors receiving tyrosine kinase inhibitors, suggesting that both malignancy and treatment contribute to vascular occlusion [8]. These findings align with our case, where breast carcinoma and chemotherapy with capecitabine likely acted synergistically to create a prothrombotic state. Malignancy is a well‐recognized hypercoagulable condition. Tumor cells release procoagulant factors such as tissue factor and cancer procoagulant, which activate the coagulation cascade [3]. Additionally, chemotherapy agents can damage vascular endothelium, further promoting thrombosis. In CRVO, Virchow's triad‐ venous stasis, endothelial injury, and hypercoagulability‐ explains the pathogenesis. In older patients, vascular rigidity and atherosclerosis dominate, whereas in younger patients, systemic hypercoagulability is often the primary driver [9]. In this case, breast carcinoma with lymphovascular invasion likely predisposed the patient to venous occlusion, compounded by chemotherapy‐induced vascular stress. In young patients presenting with CRVO, differential diagnoses include inherited thrombophilias (protein C/S deficiency, antithrombin III deficiency, factor V Leiden mutation), autoimmune disorders such as antiphospholipid antibody syndrome, and infectious causes including HIV or hepatitis [2, 10]. Medication‐induced vascular events, particularly with chemotherapeutic agents, must also be considered. In our patient, systemic workup excluded some conventional risk factors and viral infections, but thrombophilia and autoimmune causes were not assessed. Therefore, alternative prothrombotic conditions cannot be ruled out. A comprehensive thrombophilia panel, including antiphospholipid antibodies, anticardiolipin antibody, plasma homocysteine, and protein C/S activity, is recommended in such cases [11]. The management of CRVO focuses on reducing macular edema and preventing neovascular complications. Intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy remains the gold standard for macular edema secondary to CRVO, as demonstrated in pivotal randomized controlled trials such as CRUISE and COPERNICUS, and reinforced by the AAO Preferred Practice Pattern. These studies consistently show improved visual outcomes and reduced vascular leakage with anti‐VEGF therapy [12, 13, 14]. In addition, recent literature has highlighted the importance of standardized intravitreal injection protocols and peri‐procedural management to optimize safety. For example, Avogaro et al. reported on primary prevention strategies for intravitreal injections [15] while Trovato Battagliola et al. evaluated topical antibiotic prophylaxis before injections [16]. Incorporating such evidence underscores the need for careful procedural planning alongside pharmacologic therapy. In our patient, three doses of intravitreal Avastin led to significant improvement in visual acuity and macular thickness. Systemic management is equally important. Identifying malignancy as the underlying risk factor necessitates close collaboration between ophthalmology and oncology teams. While anticoagulation may be considered in patients with confirmed thrombophilia, its role in CRVO remains debated. Fluorescein angiography was not performed, limiting classification of CRVO as ischemic or non‐ischemic. This represents an important limitation. Capecitabine has been associated with systemic thromboembolic events, but evidence for retinal vascular occlusion remains limited. Its role should be considered as a potential contributing factor rather than a proven cause. Clinical Implications and Learning Points This case highlights several important clinical lessons: CRVO in young patients without conventional risk factors should prompt systemic evaluation for malignancy or hypercoagulable states.Malignancy‐associated hypercoagulability is a rare but important cause of retinal vascular occlusion.Chemotherapy agents may exacerbate vascular risk, necessitating vigilance for ocular complications.Multidisciplinary management ensures optimal outcomes, combining ophthalmic intervention with systemic cancer care.To the best of our knowledge, this case lies in the rare association between breast carcinoma and CRVO in a relatively young patient. Early recognition and treatment preserved vision and guided systemic evaluation, ultimately improving prognosis. CRVO in young patients without conventional risk factors should prompt systemic evaluation for malignancy or hypercoagulable states. CRVO in young patients without conventional risk factors should prompt systemic evaluation for malignancy or hypercoagulable states. Malignancy‐associated hypercoagulability is a rare but important cause of retinal vascular occlusion. Malignancy‐associated hypercoagulability is a rare but important cause of retinal vascular occlusion. Chemotherapy agents may exacerbate vascular risk, necessitating vigilance for ocular complications. Chemotherapy agents may exacerbate vascular risk, necessitating vigilance for ocular complications. Multidisciplinary management ensures optimal outcomes, combining ophthalmic intervention with systemic cancer care. Multidisciplinary management ensures optimal outcomes, combining ophthalmic intervention with systemic cancer care. Conclusion CRVO is rare in younger patients and usually linked to hypercoagulable states. This case highlights breast carcinoma as a plausible associated condition rather than a proven cause. Prompt recognition and intravitreal anti‐VEGF therapy led to significant visual recovery. Clinicians should consider systemic malignancy in atypical CRVO presentations to ensure timely diagnosis and multidisciplinary management. Author Contributions Hamna Danyal Barry: conceptualization, visualization, project administration, investigation, validation, writing – original draft. Erum Habib: conceptualization, data curation, formal analysis, investigation, writing – original draft. Muhammad Umer Barry: conceptualization, visualization, writing – original draft, funding acquisition, writing – review and editing. Musfirah Danyal Barry: writing – review and editing. Ayesha Barkat: investigation, methodology, funding acquisition, writing – original draft. Husam Abu Dawood: supervision, writing – original draft, writing – review and editing, visualization, investigation. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent Written informed consent was obtained from the patient for publication and any accompanying images. A copy of the written consent is available for review by the Editor‐in‐Chief of this journal on request. Conflicts of Interest The authors declare no conflicts of interest.